Multiple Myeloma
Latest interviews and perspectives
Most recent
A phase III randomized study of daratumumab with VMP versus VMP alone in newly diagnosed MM patients who are ineligible for transplant
Mateos MV, et al. ASH 2017:LBA-4 Background In the VISTA study, the addition of bortezomib to melphalan and prednisone (VMP) improved efficacy, but also increased toxicity in newly diagnosed multiple myeloma (NDMM) patients.1 Subsequent trials optimized VMP by...
A phase II study of a novel conditioning regimen of bendamustine and melphalan followed by ASCT for patients with MM
Gomez-Arteaga A, et al. ASH 2017:4546 Background In a phase I trial by Gomez-Arteaga and colleagues, the addition of bendamustine to high-dose melphalan (200 mg/m2; MEL200) showed no additional toxicity above what is expected with MEL200 alone.1 At ASH 2017, results...
Improved Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
A majority of patients with multiple myeloma (MM) relapse after therapy, and the duration of remission decreases with each line of therapy.1 Novel agents, including proteasome inhibitors (PIs) and immunomodulatory agents (IMIDs), have improved outcomes for patients...
Dr. Neil Berinstein: Insights on the Use of Montelukast in Patients with R/R Multiple Myeloma Receiving Daratumumab
This study sought to evaluate how infusion-related reactions (IRRs) related to treatment with daratumumab were affected by premedication with montelukast, a leukotriene receptor antagonist. The rationale for this stems from the high incidence of IRRs (up to 71% of...
Use of montelukast to reduce infusion reactions in an early access program of daratumumab in U.S. patients with R/R MM
Chari A, et al. ASH 2016:2142 Background Daratumumab is a CD38-directed monoclonal antibody indicated for the treatment of patients with relapsed/ refractory (R/R) multiple myeloma (MM). CD38 is expressed on airway smooth muscle cells, and infusion-related reactions...
Other
Results of an early access program of daratumumab in U.S. patients with R/R MM
Chari A, et al. ASH 2016:2133 Background A multicentre, open-label, Early Access Treatment Protocol (EAP) was opened in June 2015 after the MMY2002 study demonstrated the efficacy and safety profile of daratumumab in patients with relapsed/ refractory (R/R) multiple...
Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in R/R MM based on prior lines of therapy: Updated analysis of CASTOR
Mateos MV, et al. ASH 2016:1150 Background An early phase study of daratumumab in combination with bortezomib showed deep and durable responses in patients with multiple myeloma (MM). The combination was also well tolerated with manageable adverse events.1 The...
Dr. Richard LeBlanc: Impressive Results from POLLUX Trial
The addition of daratumumab to lenalidomide and dexamethasone (DRd) vs. lenalidomide and dexamethasone (Rd) alone was evaluated in the POLLUX trial, a randomized, open-label, multicentre, phase III study. The population of the study included 569 patients with multiple...
Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in R/R MM among patients with 1–3 prior lines of therapy: Updated analysis of POLLUX
Usmani SZ, et al. ASH 2016:1151 Background The POLLUX study has previously demonstrated deeper response with daratumumab, lenalidomide, and dexamethasone (DRd) compared to lenalidomide and dexamethasone (Rd) in patients with relapsed/ refractory (R/R) multiple myeloma...
Efficacy of daratumumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone for R/R MM among patients with 1–3 prior lines of therapy based on previous treatment exposure: Updated analysis of POLLUX
Moreau P, et al. ASH 2016:489 Background In a phase I/II study, 32 patients with relapsed or refractory (R/R) multiple myeloma (MM) were treated with daratumumab, lenalidomide, and dexamethasone (DRd), which induced rapid, deep, and durable responses with a manageable...
Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant in multiple myeloma: a meta-analysis of overall survival
Attal M, et al. ASCO 2016:8001 Background Lenalidomide maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma reduces the risk of progression or death by approximately 50% compared to ASCT alone.1–4 However,...
A phase III randomized, controlled study of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: CASTOR
Palumbo A, et al. ASCO 2016:LBA4 Background Daratumumab is a human anti-CD38 monoclonal antibody with both direct and indirect anti-myeloma activity. In a previous phase II trial, daratumumab demonstrated single-agent activity in heavily pretreated patients with...
Novel Therapies Provide Treatment Options for Patients with Relapsed and Refractory Multiple Myeloma
NE Oncology Issue - April 2016 Over the last 15 years, the overall survival (OS) of patients diagnosed with multiple myeloma (MM) has significantly improved.1 This can largely be attributed to the introduction of several new agents for the treatment of MM; most...
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
NE Oncology Issue - April 2016 Fouquet G, et al. ASH 2015:1831 Background Fouquet and colleagues examined the outcome of patients with relapsed/refractory (R/R) multiple myeloma (MM) after treatment with pomalidomide and dexamethasone (Pom-Dex). At ASH 2015, an...
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
NE Oncology Issue - April 2016 Usmani SZ, et al. ASH 2015:29 Background In the GEN5011 and SIRIUS2 (MMY2002) clinical studies, daratumumab monotherapy has demonstrated remarkable efficacy and good tolerability in heavily treated patients with relapsed and refractory...
Twitter feed